Naruse T, Amano H, Koizumi Y
Central Research Laboratories, Banyu Pharmaceutical Co Ltd, Tokyo, Japan.
Fundam Clin Pharmacol. 1991;5(8):677-93. doi: 10.1111/j.1472-8206.1991.tb00757.x.
Possible involvement of dopamine receptors in diazepam-induced (1 mg/kg, subcutaneous (sc] hyperphagia was studied in nondeprived rats. Pretreatment with the selective D-1 antagonist, SCH23390 (0.03 mg/kg, sc) inhibited diazepam-induced hyperphagia. In addition, pretreatment with the preferential D-2 antagonists, haloperidol (0.1 to 0.3 mg/kg, sc) and clebopride (0.1 to 0.3 mg/kg, sc) inhibited diazepam-induced hyperphagia in a dose-dependent manner. Pretreatment with co-administration of SCH23390 (0.1 mg/kg, sc) and clebopride (0.03 mg/kg, sc) completely inhibited this hyperphagia. The selective D-2 antagonist, sulpiride (40 mg/kg, sc) and the peripheral D-2 antagonist, domperidone (10 mg/kg, sc) did not affect diazepam-induced hyperphagia. However, sulpiride (10 micrograms, icv) or domperidone (2 micrograms, icv) administered centrally inhibited this hyperphagia. The highest dose of haloperidol (0.3 mg/kg, sc) or clebopride (0.3 mg/kg, sc) and higher doses of SCH23390 (0.01 and 0.03 mg/kg, sc) or SCH23390/clebopride (0.01/0.03 and 0.01/0.1 mg/kg, sc) tended to decrease spontaneous feeding in non-deprived rats. In addition, the highest dose of haloperidol, clebopride or SCH23390/clebopride inhibited spontaneous feeding in deprived rats. Interestingly, diazepam-induced hyperphagia was inhibited significantly by doses of haloperidol (0.1 mg/kg, sc), clebopride (0.1 mg/kg, sc) and SCH23390/clebopride (0.003/0.03 and 0.003/0.1 mg/kg, sc) which did not affect spontaneous feeding in non-deprived or deprived rats. Pretreatment with alpha-methyl-p-tyrosine (40 mg/kg, IP x 2, 6 and 2 h prior to diazepam administration) failed to inhibit this hyperphagia. Furthermore, pretreatment with a large dose of haloperidol (5 mg/kg, sc, 4 days before diazepam administration) augmented the sub-hyperphagic effect to diazepam (0.5 mg/kg, sc). Thus, these findings suggest that hyperphagia to diazepam is mediated in part by both dopamine D-1 and D-2 receptors in non-deprived rats.
在未禁食大鼠中研究了多巴胺受体可能参与地西泮诱导的(1毫克/千克,皮下注射)摄食过量。用选择性D-1拮抗剂SCH23390(0.03毫克/千克,皮下注射)预处理可抑制地西泮诱导的摄食过量。此外,用优先D-2拮抗剂氟哌啶醇(0.1至0.3毫克/千克,皮下注射)和氯波必利(0.1至0.3毫克/千克,皮下注射)预处理以剂量依赖性方式抑制地西泮诱导的摄食过量。联合给予SCH23390(0.1毫克/千克,皮下注射)和氯波必利(0.03毫克/千克,皮下注射)预处理可完全抑制这种摄食过量。选择性D-2拮抗剂舒必利(40毫克/千克,皮下注射)和外周D-2拮抗剂多潘立酮(10毫克/千克,皮下注射)不影响地西泮诱导的摄食过量。然而,中枢给予舒必利(10微克,脑室内注射)或多潘立酮(2微克,脑室内注射)可抑制这种摄食过量。氟哌啶醇(0.3毫克/千克,皮下注射)或氯波必利(0.3毫克/千克,皮下注射)的最高剂量以及更高剂量的SCH23390(0.01和0.03毫克/千克,皮下注射)或SCH23390/氯波必利(0.01/0.03和0.01/0.1毫克/千克,皮下注射)倾向于降低未禁食大鼠的自发进食量。此外,氟哌啶醇、氯波必利或SCH23390/氯波必利的最高剂量可抑制禁食大鼠的自发进食。有趣的是,氟哌啶醇(0.1毫克/千克,皮下注射)、氯波必利(0.1毫克/千克,皮下注射)和SCH23390/氯波必利(0.003/0.03和0.003/0.1毫克/千克,皮下注射)的剂量可显著抑制地西泮诱导的摄食过量,而这些剂量并不影响未禁食或禁食大鼠的自发进食。用α-甲基-p-酪氨酸(40毫克/千克,腹腔注射×2次,在地西泮给药前6小时和2小时)预处理未能抑制这种摄食过量。此外,用大剂量氟哌啶醇(5毫克/千克,皮下注射,在地西泮给药前4天)预处理增强了地西泮(0.5毫克/千克,皮下注射)的亚摄食过量效应。因此,这些发现表明,未禁食大鼠对地西泮的摄食过量部分由多巴胺D-1和D-2受体介导。